A 2016 systematic review and meta-analysis evaluated pharmacist-led medication reconciliation at hospital transitions, including 17 studies involving 21,342 adults. Interventions commonly included obtaining or confirming an accurate medication history, reconciling medications at discharge, providing discharge counseling or documentation, and conducting postdischarge telephone calls or home visits. Most included studies featured multiple transitions. Compared with usual care, these programs reduced all-cause readmissions by 19% (relative risk [RR], 0.81; 95% confidence interval [CI], 0.70-0.95) and medication-related adverse drug event hospital revisits by 67% (RR, 0.33; 95% CI, 0.20-0.53). The reduction in readmissions was significant during earlier follow-up, generally within 30 days (RR, 0.77; 95% CI, 0.60-0.98), but not during longer follow-up (RR, 0.83; 95% CI, 0.68-1.06), suggesting that the benefit may be greatest shortly after discharge. However, substantial heterogeneity, in...

READ MORE→

According to 2026 American Academy of Pediatrics (AAP) and American Society of Pediatric Hematology-Oncology clinical guidance on iron deficiency and iron deficiency anemia (IDA) in infants, children, and adolescents, intravenous (IV) iron sucrose is FDA-approved for pediatric patients over 2 years of age, carries no black box warning, and requires no test dose, distinguishing it from low-molecular-weight iron dextran. The guidance specifies a maximum FDA-approved single infusion dose of 100 mg for initial treatment and 300 mg for maintenance, administered undiluted over 5 minutes or diluted over 30 to 90 minutes. IV iron is recommended for children with refractory or persistent IDA after at least 3 months of oral therapy, particularly those with elevated hepcidin from chronic inflammatory conditions or intestinal malabsorption, and referral to a pediatric specialty center experienced in parenteral iron is advised. The guidance underscores that appropriate monitoring with staff prep...

READ MORE→

According to a 2017 American College of Obstetricians and Gynecologists (ACOG) guidance document on postpartum hemorrhage, fibrinogen concentrates are specifically approved for treating acute bleeding in patients with congenital fibrinogen deficiency. Nevertheless, limited data are available regarding the use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates in postpartum hemorrhage (PPH) and disseminated intravascular coagulation. Consequently, their use is advised only after several rounds of standard massive transfusion agents have been administered and in consultation with an expert in massive hemorrhage. The guidance does not provide recommendations for specific fibrinogen concentrate products, including Fibryga, or product-specific dosing for PPH following vaginal or cesarean delivery. [1] Several review articles have evaluated fibrinogen concentrate for PPH, with evidence suggesting that fibrinogen <200 mg/dL is associated with progression to severe P...

READ MORE→

The 2020 American College of Cardiology guidelines for management of bleeding during oral anticoagulation provide guidance on warfarin-related bleeding reversal using 4-factor prothrombin complex concentrate (4F-PCC) as a class and do not specifically mention Balfaxar. For vitamin K antagonist (VKA) reversal, 4F-PCC may be dosed using international normalized ratio (INR)-based weight-adjusted protocols or a fixed-dose approach of 1,000 units for non-intracranial major bleeding and 1,500 units for intracranial hemorrhage, with intravenous vitamin K co-administration. The guidelines do not provide fixed-dose prothrombin complex concentrate (PCC) protocols for direct oral anticoagulant-associated bleeding; instead, specific reversal agents are preferred, with PCC or activated PCC recommended as alternatives when targeted reversal agents (e.g., antidotes) are unavailable. [1] The 2025 Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) guidelines provide guidance ...

READ MORE→

According to a 2022 evidence-based dosing review from the Dutch Pediatric Formulary, intranasal (IN) dexmedetomidine 1 to 2 mcg/kg as a single dose before induction of anesthesia is recommended for premedication in pediatric patients aged 6 months to 18 years. The recommendation was developed from a risk-benefit assessment of available pediatric efficacy, safety, and pharmacokinetic evidence. For procedural sedation, experts recommend a higher IN dose of 2 to 3 mcg/kg/dose, which may be repeated if necessary, with a maximum total dose of 200 mcg. Notably, although the review establishes a 200-mcg maximum total dose for procedural sedation, it does not specify an absolute maximum dose for IN dexmedetomidine when used as preoperative premedication. [1] A 2017 systematic review and meta-analysis evaluated the efficacy and safety of intranasal dexmedetomidine for preoperative premedication in 1,190 pediatric patients across 13 randomized controlled trials. The included studies admini...

READ MORE→